What question did this study set out to answer?

To report the efficacy of the Brentuximab Vedotin and Bendamustine protocol in Hodgkin lymphoma cases.

Brentuximab Vedotin and Bendamustine Protocol in Hodgkin Lymphoma: Report of Two Cases in Abidjan, Côte d'Ivoire

View Full Paper

Ask AI

Bookmark

Authors

Case reports demonstrate targeted therapy's effectiveness in treating refractory Hodgkin lymphoma with lymphadenopathy.

To report the efficacy of the Brentuximab Vedotin and Bendamustine protocol in Hodgkin lymphoma cases.
Two case reports of patients with refractory Hodgkin lymphoma
Patients received multiple lines of treatment including AVD and EACOPP
Brentuximab Vedotin combined with Bendamustine was administered as a third-line treatment.
First patient showed good remission after the Bv-B combination
Second patient did not respond well to earlier treatments and later died after the Bv-B protocol
Both cases highlight the potential of targeted therapy in challenging cases.

Kouakou et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark